Gastroparesis Drugs Market To Grow By USD 1.42 Billion From 2024-2028, Driven By Rising Diabetes Rates And AI-Driven Market Trend Insights - Technavio

NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global
gastroparesis drugs market
size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of
3.69%
during the forecast period. Rising global burden of diabetes
is driving market growth,
with a trend towards
increasing growth opportunities in emerging markets. However,
stringent regulatory guidelines
poses a challenge. Key market players include Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc..

AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now

Key Market Trends Fueling Growth

Vendors in the gastrointestinal drugs market are expanding their businesses in emerging economies to tap into the growing number of undiagnosed and untreated patients with gastrointestinal disorders. For instance, the incidence and prevalence of chronic gastrointestinal disorders in Asia, particularly in China and India, have been rising. Abbott, a leading player, is focusing on expanding its R&D teams and manufacturing facilities in these markets to improve its product offerings and launch new ones. In 2022 and 2021, Abbott's Established Pharmaceutical Products segment sales grew by 10.6% and 10.4% respectively, driven by increased sales in countries like India, China, and Brazil. Abbott's investment in infrastructure, including manufacturing facilities, strengthens its sales and service capabilities and maximizes growth opportunities in these markets. The expanding presence of vendors in emerging economies will positively impact the growth of the gastrointestinal drugs market during the forecast period.

The Gastroparesis Drugs Market is experiencing significant growth due to the rising prevalence of gastroparesis, a condition characterized by hindered digestion leading to symptoms like vomiting and abdominal discomfort. This condition can lead to complications such as blood sugar regulation issues and nutrient absorption problems. Post-surgical gastroparesis and diabetic gastroparesis, particularly in diabetic cases, are major drivers of the market. FDA clearance for innovative drugs like Neurogastrx's tradipant, metopimazine, deudomperidone, and metoclopramide from companies like Neurogastrx, ANI Pharmaceuticals, Evoke Pharma, and others, is fueling market expansion. Antiemetics like Erythromycin and Reglan are also used for symptom management. Clinical trials for new treatments, including those for autonomic neuropathy, are ongoing. Hospitals and specialized care centers are key markets for gastroparesis drugs, with surgical interventions for acute conditions like acute cholecystitis and acute pancreatitis also driving demand. Lifestyle factors like diabetes, alcohol consumption, and tobacco consumption contribute to the condition's prevalence.

Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!

Market
Challenges

• The Gastroparesis Drugs Market is subjected to rigorous regulation by authorities like the US FDA and EMA to ensure drug safety and efficacy. Regulatory bodies scrutinize pharmacological data, pharmacodynamic effects, drug interactions, and other criteria before approving drugs. Failure to meet these standards may result in a complete response letter (CRL) or rejection. Applicants must then provide additional data, often requiring more clinical trials, increasing R&D costs. Clinical trials consist of three phases: Phase I (safety and efficacy), Phase II (dose-ranging), and Phase III (documenting efficacy and safety). Regulatory agencies may halt trials if concerns arise. The drug development process involves significant financial investment due to the need for a sterile environment and adherence to good manufacturing practices (GMP). Variations in these practices can lead to significant differences in results, necessitating stringent regulations. However, these guidelines may hinder market growth due to increased costs and time-consuming processes.
• The Gastroparesis Drugs Market faces challenges due to symptoms like vomiting and abdominal discomfort. Blood sugar regulation and nutrient absorption complications are major concerns. Surgical procedures and post-surgical gastroparesis require FDA clearance for new treatments. Prokinetic agents like Erythromycin, Antiemetics , Reglan, Neurogastrx's tradipant, metopimazine, deudomperidone, and metoclopramide hinder digestion. Enteral nutrition and feeding intolerance are common in diabetic gastroparesis cases, particularly in hospitals and during surgical interventions. Diabetes, lifestyles (alcohol consumption, tobacco consumption), and autonomic neuropathy contribute to gastroparesis. Innovative drugs are in clinical trials to manage symptoms like nausea and improve patient care. PubMed Central reports on Acute cholecystitis, Acute pancreatitis, and gastroparesis research. Evoke Pharma and ANI Pharmaceuticals are key players.

Insights into how AI is reshaping industries and driving growth-
Download a Sample Report

Segment Overview

This gastroparesis drugs market report extensively covers market segmentation by